NAPLEX (North American Pharmacist Licensure Examination) Practice Exam

Disable ads (and more) with a membership for a one time $2.99 payment

Prepare for the NAPLEX (North American Pharmacist Licensure Examination) Test. Study with flashcards and multiple choice questions, each question has hints and explanations. Get ready for your exam!

Each practice test/flash card set has 50 randomly selected questions from a bank of over 500. You'll get a new set of questions each time!

Practice this question and more.

Omalizumab (Xolair) is indicated for?

Moderate-severe persistent allergic asthma
Chronic obstructive pulmonary disease (COPD)
Mild intermittent asthma
Acute asthma attacks

The correct answer is: Moderate-severe persistent allergic asthma

Omalizumab (Xolair) is indicated for moderate-severe persistent allergic asthma. It is a monoclonal antibody that is specifically approved for use in patients with allergic asthma that is not controlled with inhaled corticosteroids. The drug works by blocking immunoglobulin E (IgE), which is responsible for triggering allergic reactions in the body. Therefore, option A is the correct choice as it accurately reflects the approved indication for omalizumab. Options B, C, and D are incorrect: B. Chronic obstructive pulmonary disease (COPD): Omalizumab is not indicated for COPD as it is specifically approved for allergic asthma. C. Mild intermittent asthma: Omalizumab is used for moderate-severe persistent allergic asthma, not for mild intermittent asthma. D. Acute asthma attacks: Omalizumab is not used for acute asthma attacks, rather it is a long-term controller medication for persistent allergic asthma.